Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that causes high rates of disability and mortality worldwide because of severe progressive and irreversible symptoms. During the period of COPD initiation and progression, the immune system triggers the activation of vari...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.695957/full |
| id |
doaj-47961e7224f543c694659c786e152857 |
|---|---|
| record_format |
Article |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Meiling Liu Kang Wu Kang Wu Jinduan Lin Qingqiang Xie Yuan Liu Yin Huang Jun Zeng Zhaogang Yang Yifan Wang Shiyan Dong Weiye Deng Mingming Yang Song Wu Song Wu Wen Jiang Xuefeng Li Xuefeng Li |
| spellingShingle |
Meiling Liu Kang Wu Kang Wu Jinduan Lin Qingqiang Xie Yuan Liu Yin Huang Jun Zeng Zhaogang Yang Yifan Wang Shiyan Dong Weiye Deng Mingming Yang Song Wu Song Wu Wen Jiang Xuefeng Li Xuefeng Li Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? Frontiers in Pharmacology IL-17A COPD inflammation cytokine chemokine treatment |
| author_facet |
Meiling Liu Kang Wu Kang Wu Jinduan Lin Qingqiang Xie Yuan Liu Yin Huang Jun Zeng Zhaogang Yang Yifan Wang Shiyan Dong Weiye Deng Mingming Yang Song Wu Song Wu Wen Jiang Xuefeng Li Xuefeng Li |
| author_sort |
Meiling Liu |
| title |
Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? |
| title_short |
Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? |
| title_full |
Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? |
| title_fullStr |
Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? |
| title_full_unstemmed |
Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease? |
| title_sort |
emerging biological functions of il-17a: a new target in chronic obstructive pulmonary disease? |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Pharmacology |
| issn |
1663-9812 |
| publishDate |
2021-07-01 |
| description |
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that causes high rates of disability and mortality worldwide because of severe progressive and irreversible symptoms. During the period of COPD initiation and progression, the immune system triggers the activation of various immune cells, including Regulatory T cells (Tregs), dendritic cells (DCs) and Th17 cells, and also the release of many different cytokines and chemokines, such as IL-17A and TGF-β. In recent years, studies have focused on the role of IL-17A in chronic inflammation process, which was found to play a highly critical role in facilitating COPD. Specially, IL-17A and its downstream regulators are potential therapeutic targets for COPD. We mainly focused on the possibility of IL-17A signaling pathways that involved in the progression of COPD; for instance, how IL-17A promotes airway remodeling in COPD? How IL-17A facilitates neutrophil inflammation in COPD? How IL-17A induces the expression of TSLP to promote the progression of COPD? Whether the mature DCs and Tregs participate in this process and how they cooperate with IL-17A to accelerate the development of COPD? And above associated studies could benefit clinical application of therapeutic targets of the disease. Moreover, four novel efficient therapies targeting IL-17A and other molecules for COPD are also concluded, such as Bufei Yishen formula (BYF), a Traditional Chinese Medicine (TCM), and curcumin, a natural polyphenol extracted from the root of Curcuma longa. |
| topic |
IL-17A COPD inflammation cytokine chemokine treatment |
| url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.695957/full |
| work_keys_str_mv |
AT meilingliu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT kangwu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT kangwu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT jinduanlin emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT qingqiangxie emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT yuanliu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT yinhuang emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT junzeng emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT zhaogangyang emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT yifanwang emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT shiyandong emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT weiyedeng emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT mingmingyang emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT songwu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT songwu emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT wenjiang emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT xuefengli emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease AT xuefengli emergingbiologicalfunctionsofil17aanewtargetinchronicobstructivepulmonarydisease |
| _version_ |
1721316372198195200 |
| spelling |
doaj-47961e7224f543c694659c786e1528572021-07-07T10:49:43ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.695957695957Emerging Biological Functions of IL-17A: A New Target in Chronic Obstructive Pulmonary Disease?Meiling Liu0Kang Wu1Kang Wu2Jinduan Lin3Qingqiang Xie4Yuan Liu5Yin Huang6Jun Zeng7Zhaogang Yang8Yifan Wang9Shiyan Dong10Weiye Deng11Mingming Yang12Song Wu13Song Wu14Wen Jiang15Xuefeng Li16Xuefeng Li17The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaShenzhen Luohu People’s Hospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaSouth China Hospital, Shenzhen University, Shenzhen, ChinaThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaDepartment of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesDepartment of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX, United StatesShenzhen Luohu People’s Hospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaSouth China Hospital, Shenzhen University, Shenzhen, ChinaDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United StatesThe Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People’s Hospital; State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, ChinaShenzhen Luohu People’s Hospital, The Third Affiliated Hospital of Shenzhen University, Shenzhen, ChinaChronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease that causes high rates of disability and mortality worldwide because of severe progressive and irreversible symptoms. During the period of COPD initiation and progression, the immune system triggers the activation of various immune cells, including Regulatory T cells (Tregs), dendritic cells (DCs) and Th17 cells, and also the release of many different cytokines and chemokines, such as IL-17A and TGF-β. In recent years, studies have focused on the role of IL-17A in chronic inflammation process, which was found to play a highly critical role in facilitating COPD. Specially, IL-17A and its downstream regulators are potential therapeutic targets for COPD. We mainly focused on the possibility of IL-17A signaling pathways that involved in the progression of COPD; for instance, how IL-17A promotes airway remodeling in COPD? How IL-17A facilitates neutrophil inflammation in COPD? How IL-17A induces the expression of TSLP to promote the progression of COPD? Whether the mature DCs and Tregs participate in this process and how they cooperate with IL-17A to accelerate the development of COPD? And above associated studies could benefit clinical application of therapeutic targets of the disease. Moreover, four novel efficient therapies targeting IL-17A and other molecules for COPD are also concluded, such as Bufei Yishen formula (BYF), a Traditional Chinese Medicine (TCM), and curcumin, a natural polyphenol extracted from the root of Curcuma longa.https://www.frontiersin.org/articles/10.3389/fphar.2021.695957/fullIL-17ACOPDinflammationcytokinechemokinetreatment |